Learn about conditional reimbursement from the interview with CEO Jarmo Hahl, Medaffcon Oy.
There’s often uncertainty about total costs, cost-effectiveness and therapeutic value of new medicines. As a new method for controlling these uncertainties the so called conditional reimbursement procedure, Finnish version of Risk Sharing Agreements, for retail medicines has been introduced. It aims at safeguarding the access of Finnish patients and health care professionals to new effective medicines in sustainable way.
The opportunity to conditional reimbursement will primarily affect new medical treatments. In practice, this means new medical substances or new significant therapeutic indications of medicinal products already approved for reimbursement. The resulting agreement will include the conditions for monitoring and controlling the uncertainty of the medicinal product.
At the moment, the provisions on conditional reimbursement will remain valid for a fixed term, to the end of 2019. However, it would be beneficial to have a permanent legislation in place to secure the continuation of this new procedure which evidently has been well received by all stakeholders involved. Also, to be able to utilize the opportunities in full in Finnish health care, the availability of register data and utilization in different forms also for the purposes of monitoring conditional reimbursement agreements is of great importance.
Market Access, pricing and reimbursement of medicines in Finland – This article provides information of the market access options and current pricing system in Finland, in ambulatory and hospital care.
Risk-sharing agreement services – By combining Medaffcon’s extensive expertise and Tamro’s Risk-Sharing Model Management System TamroLINK, we provide a comprehensive solution for implementing risk-sharing models.
Health economic modelling services – Modelling compiles fragmented research data, observations, experiences, and justified assumptions, into a synthesis to anticipate and predict the impact of healthcare interventions on individuals, patient groups, healthcare and society.
Pricing and reimbursement services – Optimally, a new treatment is available to patients as quickly and extensively as possible and at a competitive price. Medaffcon provides support at all stages of the pivotal price and reimbursement application process.
Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
Timo Karvinen joined Medaffcon’s Market Access team as an expert in the beginning of May. In addition to his extensive expertise, he also brings a whole new service concept to Medaffcon.